Optimize: Heart & Blood Pressure

The foundational blood-pressure lever. DASH pattern plus sodium reduction drops systolic ~9 mmHg vs a high-salt Western diet; the drop scales with starting pressure. A potassium salt substitute cut stroke 14% and CV events 13% in a hard-outcome RCT (SSaSS, PMID 34459570). Reduce-lever framing (less sodium, more potassium). Note the PURE J-curve honestly: very low intake (<3 g) also tracks with risk, so the target is moderation, not zero.

~30% fewer heart attacks, strokes and cardiac deaths (PREDIMED); BP, lipids and glucose improve within 3 months before weight loss. Empower-first dietary pattern that carries the whole cardiometabolic load at once. PREDIMED was retracted and republished after randomization irregularities, so state the effect at its true, slightly-softened strength.

Reduce-lever: heaviest ultra-processed intake tracks with ~30% more heart disease and ~50% higher CV death. Observational, so name the confounders (overall diet, income, activity). Cutting UPF is the same move as the Mediterranean/DASH patterns from the other direction.

Accessible aerobic base. ~7,000 steps/day vs 2,000 tracks with 25% less heart disease; RCTs show ~3.6 mmHg systolic drop. Energy-matched, walking equals running on BP and lipids. Free, no equipment, works for most readers.

Cardiorespiratory fitness is one of the strongest predictors of CV death; each 1-MET gain tracks with 13% lower mortality and 15% fewer events. The fitness NUMBER is a marker (track it), but training to raise it is a genuine lever. Empower-first.

Soluble fibre lowers LDL dose-dependently: psyllium ~13 mg/dL at 10 g/day, oat beta-glucan ~7 mg/dL. Each +7 g/day tracks with 9% lower CV risk. A food-first lipid and event lever that costs almost nothing.

Lowers BP most in prehypertension (~4/4 mmHg). Best as a complement to aerobic work, not a standalone BP cure. Foundational for the broader cardiometabolic picture.

Semaglutide cut major CV events ~20% in obesity WITHOUT diabetes (SELECT) and ~26% in high-risk type 2 diabetes. Genuine hard-outcome benefit. Empower-first placement: named calmly AFTER the lifestyle basics as an earned option for higher-risk readers, not the headline. Disclose manufacturer (Novo Nordisk) funding of the pivotal trials.

Empagliflozin cut CV death 38% (EMPA-REG); dapagliflozin cut worsening heart failure or CV death 26% with or without diabetes (DAPA-HF). A clinical lever for heart-failure and high-CV-risk readers, named calmly after basics. Disclose manufacturer funding.

Intervals and steady work lower BP about equally; intervals raise VO2max more per minute. A time-efficient option, not superior for BP. Good for readers short on time who can tolerate hard efforts.

Merge grip-training here (duplicate topic). Isometric handgrip produced the largest resting-SBP drop of any exercise mode in network meta-analysis (~8 mmHg), confirmed in individual-patient data (~6 mmHg). Honest limits: effect fades on detraining and 24-hour ambulatory data are thin. A strong adjunct, not a foundation.

Acute BP drops up to 10/8 mmHg; daily juice held 24-hour BP ~7.7/5.2 lower in hypertension. State the honest null: added to a normal diet it did NOT lower whole-day BP in free-living trials. Useful, context-dependent.

Modest BP lowering (~2 mmHg, ~4 in high starters) and better endothelial function. But COSMOS, the large RCT, missed its primary CV-event endpoint (HR 0.90, P=0.11); the 27% CV-death drop was a secondary endpoint. Present at true, softened strength.

~2 mmHg systolic across 34 trials; dietary magnesium tracks with less heart failure and stroke (observational). Small effect, food-first (greens, legumes, nuts). Reasonable for readers low in dietary magnesium.

Lowers systolic ~10 mmHg (Western trials) with larger, lower-quality effects in Chinese trials. Two-lens: a durable movement tradition with real BP data. Honest: did not improve heart-failure exercise capacity.

~5/4 mmHg, and 11/6 with added breathing and meditation; the effect shrinks against active comparators rather than waitlist. Sustainable, low-risk.

Slow and alternate-nostril breathing lowered systolic ~7 mmHg across trials. Small, likely partly autonomic/expectation-mediated; free and safe.

Honest split by dose and population: high-dose prescription EPA cut events ~25% in high-triglyceride patients (REDUCE-IT), but standard 1 g capsules failed in VITAL and ASCEND, high-dose EPA+DHA failed in STRENGTH, and Cochrane pooling is near-null. Triglyceride lowering (~20-30% at 4 g) is real and strong. Situational: a high-TG lever, not a general prevention supplement. Watch the REDUCE-IT mineral-oil-comparator critique (symmetric skepticism).

UKPDS: 36% lower all-cause mortality in overweight type 2 diabetes. A CV-relevant lever chiefly for people who already have diabetes, not a general heart drug. Named calmly.

Q-SYMBIO: fewer major heart-failure events (15% vs 26%) and deaths in established heart failure; pooled HF mortality RR 0.69. Be precise: this is a HEART-FAILURE lever, NOT a blood-pressure lever (BP change was non-significant). Do not surface it on a general BP page.

Reduce-lever. Above ~2 drinks/day, cutting back lowers BP and cut atrial-fibrillation recurrence to 53% from 73%; genetic (Mendelian) data show higher intake raises hypertension and coronary risk. Below 2 drinks/day the BP change was not significant, so frame honestly, not as a blanket command.

Honest two-sided picture: regular caffeine nudges BP up ~4/2 mmHg, yet moderate coffee tracks with 40-48% lower cardiometabolic disease and does NOT raise atrial fibrillation. Not a BP-lowering lever; relevant as reassurance that moderate coffee is cardio-neutral to beneficial for most.

Slow-breathing BP benefit largely vanished (5.62 mmHg to none) once sham controls were added; 15 days of Wim Hof moved nothing. Keep as emerging, do not oversell device-guided breathing for hard BP outcomes.

Lowers LDL ~18-25 mg/dL and triglycerides ~30-44 mg/dL. Real lipid signal but small, mostly lower-quality Chinese trials with bioavailability caveats. A situational plant lever for readers wanting a food-adjacent option; disclose supplement-quality variability.

Small: total cholesterol ~7 mg/dL and systolic ~2 mmHg lower. Minor, safe, food-first.

DOWNGRADED from 'strong'. Merge the duplicate heat topics (contrast-therapy, sauna-alternatives) here: they all cite the same small hot-water-immersion FMD study (Brunt, ~n20) and observational Finnish sauna cohorts. FMD is a surrogate and sauna mortality data are confounded, so this is emerging, not strong. Pleasant and plausible; not established for hard CV outcomes. See overGradedTiers.

BP runs ~3 mmHg lower in a forest than a built environment, but no clear sign it persists between visits. Merge nature-exposure here. Real acute effect, restorative, no durability claim.